Theodore Alexandrov is a team leader at the European Molecular Biology Laboratory (EMBL), the Europe’s leading life science laboratory. He is also the head of the EMBL Metabolomics Core Facility and an Assistant Adjunct Professor at the Skaggs School of Pharmacy, University of California San Diego, USA. The Alexandrov team at EMBL aims to reveal the secrets of metabolism in time and space in tissues and single cells by developing experimental and computational methods. The team unites interdisciplinary scientists from biology, chemistry, and computer science as well as software engineers and data analysts. The developed computational methods are integrated into various open-source and industrial software packages. Since 2014, the team develops and provides for free the cloud software METASPACE for metabolite ID in imaging mass spectrometry, used by universities, governmental organizations, and pharma companies. Theodore Alexandrov is a grantee of an ERC Consolidator project focused on studying metabolism in single cells, as well as of various other European, national, NIH, and industrially-funded projects. He has co-founded and scientifically directed the company SCiLS and has over 80 journal publications and 6 patents in the field of spatial and single-cell -omics.

Prof. Domenico ALVARO, Full Professor of Gastroenterology, Sapienza University of Rome, Italy.  Main activities and responsibilities:”2020-present: Dean of the Faculty of Medicine and Dentistry, Sapienza University of Rome;  2003-present, Teaching Patologia Integrata III, CCLE2003-present, Teaching at Scuola di Specializzazione Gastroenterologia , Sapienza Rome2004-present, Appointed Coordinator of Patologia Integrata III, Medical School Faculty, CCLA Sapienza Univ. of Rome, Italy2005-present, Teaching at Master in Experimental and Clinical Hepatology2008-Present, Editorial Board Digestive and Liver Diseases, 2018-present, Editorial board Liver International2008-2010, President Italian Society Gastroenterology (Sezione Lazio)2008-2016, Responsabile (law)-Editor of Digestive and Liver Disease2010-present, Member of Medical Academy of Rome2010-2’17, Chief of the Latina Regional Center for Celiac Disease2011-present, Member of Editorial Board Hepatology2011-2012, Member Working Team, Italian Drug Agency (AIFA)2011-2016, Member of steering committee Department of “Scienze e Biotecnologie Medico-Chirurgiche”, University of Rome “Sapienza”.2014-2017, Responsible of the Centre of Rare Disease, ASL Latina2015-2017, Member of the Faculty Committee for the appointment of Professor Emeritus2015-present, Representative of the Sapienza University in the consortium for organ transplant2016-2018 Member of the steering committee Italian Society of Gastroenterology2018-present. President of Italian Society of Gastroenterology (SIGE)2018-present Chief of Department of Translational and Precision Medicine, University of Rome Sapienza, Italy2019-present Chief of the Department of Internal Medicine and Medical Specialties 2018-present: Director of STITCH (Sapienza Information-Based Technology Innovation Center for Health2019-present: member of Academic Senate SAPIENZA Personal skills and competences: Research activity in the field of liver damage, liver regeneration, drug-induced liver damage, drug-transporters in the liver, hepatic cell proliferation and apoptosis, cholestasis, liver disease pathophysiology and treatment, Hepatic Stem-cells, regenerative medicine of liver and pancreas, cholangiocarcinoma.Scientific activities: Full papers= 327; H.Index.= 77, total citations=8954; N. 4 International patents

Dr. Jesper B. Andersen received his Ph.D. in 2006 from the Department of Molecular and Structural Biology Aarhus University, Denmark, following a research fellowship (2003-2007) in the laboratory of Dr. Bret A. Hassel at the University of Maryland, Marlene and Stewart Greenebaum Cancer Center Baltimore, USA. From 2007 to 2014, he joined the laboratory of Prof. Snorri S. Thorgeirsson at the National Cancer Institute, National Institutes of Health (NIH) Maryland, USA. At NIH, he started a translational pharmacogenomics and epigenomics program focused on human hepatobiliary cancers. In 2014, Dr. Andersen was appointed Associate Professor and group leader in translational research at Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences University of Copenhagen, Denmark. He has published more than 65 seminal papers and book chapters, received several prestigious merit awards in cancer research, most recently from the Danish Cancer Society, 2015. In 2017, Dr. Andersen was elected to the editorial board of Hepatology. His laboratory has received many competitive investigator awards and grants from the Novo Nordisk Foundation (Hallas-Møller), AP Møller Foundation, Lundbeck Foundation, Danish Cancer Society, Danish Medical Research Council for elite science in Denmark, and several postdoc fellowships from Marie Sklodowska-Curie European Research Council and The EASL. In 2015, Dr. Andersen co-founded the European Network for the Study of Cholangiocarcinoma, which includes members from more than 13 European countries. In addition, Dr. Andersen ‘s lab is involved in many research networks. including The Cancer Genome Atlas, USA. The main emphasis of Dr. Andersen’s research focus is within hepatobiliary malignancies to understand the mechanisms that contribute to tumor heterogeneity and leverage molecular data to elucidate markers that are prognostic, predictive of treatment benefit and how these alterations are involved in drug resistance. The lab utilizes genome-wide approaches in modeling disease causality, stratifying patients for advancing diagnostic and prognostic markers and therapy. The outcome of his research at BRIC aims to significantly impact clinical trial design for hepatobiliary cancer patients to improve patients prognosis through efficient selection for better therapy and to facilitate individualized therapy ‘right drug for the right patient’.

Professor Jesus M Banales

Jesus M Banales is Professor of Molecular Biology and Head of the Liver Diseases Group at the Biodonostia Health Research Institute – Donostia Univ. Hospital in San Sebastian (Spain). Prof. Banales is an international expert on the study of liver pathobiology, from health to disease, with more than 20 years of experience in basic, translational and clinical research. His multidisciplinary group is chiefly focused on studying the molecular mechanisms involved in liver pathobiology, with special attention to cholestatic liver diseases (primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and polycystic liver disease (PLD)), non-alcoholic fatty liver disease (NAFLD), and liver cancer (hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA)), and looking for novel diagnostic and therapeutic strategies.

He is also Prof. Sciences at the Univ. Navarra (Spain), and Assistant Prof. Medicine/Sciences at the Mayo Clinic (USA) and Univ. Area Andina (Colombia).

Professor Banales is also: Co-founder (2015) and Coordinator (2015-2022) of the European Network for the Study of Cholangiocarcinoma (ENS-CCA);Vice-Chair of the European COST Action EURO-CHOLANGIONET on Cholangiocarcinoma; Coordinator of the “Cancer Task Force” of the International Primary Sclerosing Cholangitis Study Group (IPSCSG); Steering Committee Member of the Global Cholangiocarcinoma Alliance (GCA); Steering Committee Member of the African Hepatopancreatico-biliary Cancer Consortium (AHPBCC); Coordinator of the Ibero-Latin American Research Network on Cholangiocarcinoma (ILARN-CCA); Member of the Governing Board AEEH (Spanish Association for the Study of the Liver); Member of the EASL Educational Committee (European Association for the Study of the Liver); and Member of ERN-Rare Liver Diseases (EU H2020).

Professor Banales is author in >200 research articles published in referent international Journals, has obtained >40 research projects as PI funded by National and International Institutions (including EU Horizon 2020), is inventor of 5 patents (3 licentiated), has supervised 15 doctoral thesis and 9 Master students, and is Member of the Editorial Boardof Hepatology, Nature Reviews Gastroenterology & Hepatology, Liver Transplantation, Seminars in Liver Diseases, Cells, and Special Section Editor of Journal of Hepatology. Finally, he was awarded with different national and international prizes for his significant research career (EASL YI Award 2018; UEG Rising Star 2018; “Ser Navarra Research Award 2020”, among others).

Dr. Irene Bargellini is an interventional radiologist at the University Hospital of Pisa, Italy.

Robert Barouki, MD, PhD, is Professor of Biochemistry at University of Paris and head of the Inserm unit T3S: “Toxicology, Therapeutic Targets, cellular Signaling and Biomarkers”. He also heads the clinical metabolomics and proteomic biochemistry laboratory at the Necker Enfants malades hospital. His research is focused on the impact of environmental contaminants on human health, in particular POPs and EDCs. He is involved in several EU projects: HBM4EU (linking exposure to health), Heals and Neurosome (exposome), HERA (setting the research agenda in environment and health)and Oberon (EDC testing). He has also been involved in the networking of French and European research in the field of environment and health as well as in communicating scientific data to citizens.

Annalisa Berzigotti graduated in Medicine in Bologna, Italy, where she also obtained the title of specialist in Internal Medicine and a Doctorate in ultrasound in medicine. She focused on liver disease early in her career, and expanded her knowledge in this field at the Liver Unit of the Hospital Clinic, University of Barcelona, Spain, where she obtained an academic Doctorate in hepatology. In December 2014 she joined the hepatology group of the Department of Visceral Surgery and Medicine, Bern University Hospital, Switzerland. Since 2016 she is Associate Professor of Hepatology at the University of Bern, and since March 2021 she is head of the liver group and ad interim clinic director. Annalisa Berzigotti has been member of the Governing Board of the European Association for the Study of the Liver in 2016-2019. Since 2022 she is Liver Representative at the United European Gastroenterology (UEG) Council. She is Associate Editor of the Journal of Hepatology and of Seminars in Liver Disease. She is author/co-author of 205 peer-reviewed articles. Her research interest include portal hypertension, non-invasive assessment of liver disease, the interaction of obesity and liver disease and liver transplantation.

Jordi Bruix is Professor of Medicine at the University of Barcelona and Director of the Barcelona Clinic Liver Cancer Group. He has been principal investigator of studies and clinical trials that have changed practice in the field of HCC, this including development of diagnostic criteria and prognostic models, and establishing chemoembolization, sorafenib and regorafenib as conventional therapy. He has developed and sequentially updated the BCLC staging and treatment strategy that has been endorsed by several international scientific associations to guide management of patients with HCC. He has authored more than 300 peer reviewed manuscripts and Evidence-based Practice Guidelines for Hepatocellular Carcinoma at EASL, AASLD and WGO. Dr. Bruix is a member of the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD). He founded the International Liver Cancer Association (ILCA) and was nominated President from 2006 to 2009. His task has primed major recognitions such as the Hans Popper Award, the Golden Medal Award from the Canadian Association for the Study of the Liver, the EASL Recognition Award and the AASLD Distinguished Achievement Award. He has been Associate Editor of Journal of Hepatology, Liver Transplantation and Hepatology, and Co-Editor in Chief of Seminars in Liver Disease. Currently, Associate Editor in Hepatology.

Pr Julien Calderaro is Full Professor in the Department of Pathology of Henri Mondor University Hospital in Créteil, France. He is specialized in the field of liver diseases and tumors diagnosis. His works noticeably led to the establishment of a refined morphomolecular classification of liver cancer. He now focuses his research on the immune micro-environment of liver cancers and develops innovative, artificial-intelligence based approaches to extract meaningful prognostic and molecular data from digital histological slides.

I had my medical training in Rome at Universidad Campus Bio-Medico and completed my postgraduate training in Internal Medicine in the same university hospital in 2008. Since the very beginning of my career I was specifically dedicated to liver diseases. In 2008 I moved to Universidad de Navarra, Pamplona (Spain) and started my PhD studies under the direction of Prof. Bruno Sangro, working on liver cancer and radioembolization. I´ve been working as Hepatologist in the Liver Unit of the same university hospital until now, attending patients with liver cancer and chronic liver diseases in different settings including liver transplantation. As translational researcher, I’ve been working in phase 1 and phase 1-2 clinical trials of gene and cell therapy for the treatment of different types of liver diseases including metabolic disorders, such as acute intermittent porphyria, liver cirrhosis and chronic hepatitis, as well as in several clinical trials for the treatment of liver cancer with several agents, including radioembolization, immunotherapy and targeted therapies. Between 2015 and 2017 I had my postdoctoral training in the Liver Disease Deparment of Icahn School of Medicine at Mount Sinai Hospital, New York (USA), under the direction of Dr. Augusto Villanueva, working on liquid biopsy in liver cancer. I am the national coordinator of the spanish group for the study of porphyrias (GEEP) since 2019. I am assistant professor at the Faculty of Medicine at Universidad de Navarra, Spain.

Dr. Galle majored in internal medicine at the Universities of Berlin and Marburg/Germany, Hammersmith Hospital, London/UK and University of Texas/USA and received his M.D. degree from Marburg University and Ph.D. degree from Heidelberg University. Initially he held a position as postdoctoral fellow in Molecular Biology at the Centre for Molecular Biology Heidelberg working on the replication of hepatitis B viruses. Afterwards he completed his residency in Internal Medicine and Gastroenterology at the University Hospital of Heidelberg. In 1998 he became Director of the I. Medical Department in Mainz and from 2005 – 2008 he hold the CEO position of Mainz University Hospital. He is member of several national and international societies such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), served as Co-editor for the Journal of Hepatology and is on the Editorial Boards of several other Journals. He served as congress president of the German Society for Digestive Diseases (DGVS) in 2014. He was member of the Executive Board and President of the International Liver Cancer Association (ILCA). His research has focused on elucidating important aspects of apoptotic cell death in the liver, immune escape of tumour cells and on clinical and molecular aspects of hepatocellular carcinoma. He was awarded several prizes, amongst others the prestigious Tannhauser award, the highest prize of the German Society for Digestive Diseases. He has published more than 500 peer-reviewed papers.

Nathalie Ganne-Carrié is Professor in Hepatology, head of the liver unit of the Hôpitaux Universitaires Paris Seine Saint-Denis, France (Avicenne, Bobigny) in which more than 50% of the activity is dedicated to primary liver tumor, and a clinical researcher at INSERM U1138. She has gained her medical degree in Hepato-Gastroenterology in 1992 and in Oncology in 2013 from the University of Paris 6, and completed a PhD in University of Lyon 1 in 2004 and a Higher Degree for Research (HDR) at the University of Paris 13 in 2010. Since 2019, she is the general secretary of AFEF, the French Society of Hepatology, and also member of the board of SNFGE, the French Society of Hepato-Gastroenterology. Professor Ganne-Carrié’s research interests focus on the complications of cirrhosis in particular hepatocellular carcinoma using local ressources and French national cohorts (CIRRAL, CirVir, HEPATHER) in several aspects including early detection, therapeutic innovations, and prognosis. She is the Scientific Coordinator of the French National cohort CIRRAL, which is a prospective follow-up of 652 patients with compensated alcohol-related cirrhosis in 22 centres across France and Belgium. This cohort allowed the achievement of several publications since 2018 in major international journals including Journal of Hepatology. She has published more than 200 papers and book chapters, and is an ad hoc reviewer for Journal of Hepatology and numerous other scientific journals including Lancet Gastroenterology and Hepatology, Hepatology, and Liver International.

Tim F. Greten, M.D., received his medical training at the Christian Albrechts University in Kiel, Germany. He did his internship in Munich followed by a 3-year postdoctoral fellowship at the Johns Hopkins University (Baltimore, Maryland), where he initiated his work in the field of tumor immunology. In 1999, Dr. Greten returned to Hannover Medical School, where he finished his training in Internal Medicine (2003), Medical Oncology (2004) and Gastroenterology (2007). He held an Associate Professor position in the Department of Gastroenterology, Hepatology and Endocrinology in Hannover Medical School. In February 2010, Dr. Greten joined CCR’s Medical Oncology Branch as the head of the Gastrointestinal Malignancy Section and was promoted as a tenured Senior Investigator in 2015 and Deputy Branch Chief in 2018. Dr. Greten has published more than 200 peer-reviewed papers in different journals including Science, Nature, Cell, Cancer Cell, Cancer Discovery and New England Journal of Medicine. Dr. Greten is co-chair of the Center of Excellence in Immunology and co-director of the NCI CCR.

Nathalie Ganne-Carrié is Professor in Hepatology, head of the liver unit of the Hôpitaux Universitaires Paris Seine Saint-Denis, France (Avicenne, Bobigny) in which more than 50% of the activity is dedicated to primary liver tumor, and a clinical researcher at INSERM U1138. She has gained her medical degree in Hepato-Gastroenterology in 1992 and in Oncology in 2013 from the University of Paris 6, and completed a PhD in University of Lyon 1 in 2004 and a Higher Degree for Research (HDR) at the University of Paris 13 in 2010. Since 2019, she is the general secretary of AFEF, the French Society of Hepatology, and also member of the board of SNFGE, the French Society of Hepato-Gastroenterology. Professor Ganne-Carrié’s research interests focus on the complications of cirrhosis in particular hepatocellular carcinoma using local ressources and French national cohorts (CIRRAL, CirVir, HEPATHER) in several aspects including early detection, therapeutic innovations, and prognosis. She is the Scientific Coordinator of the French National cohort CIRRAL, which is a prospective follow-up of 652 patients with compensated alcohol-related cirrhosis in 22 centres across France and Belgium. This cohort allowed the achievement of several publications since 2018 in major international journals including Journal of Hepatology. She has published more than 200 papers and book chapters, and is an ad hoc reviewer for Journal of Hepatology and numerous other scientific journals including Lancet Gastroenterology and Hepatology, Hepatology, and Liver International.

Prof. Mathias Heikenwälder is a trained molecular biologist, with expertise in immunology and a strong link to translational research evoked by 10 years of work and expertise in a Pathology Institution (Clinical Pathology, University Hospital Zurich). Since October 2015 he is Department head at the German Cancer Research Center (DKFZ) in Heidelberg focusing on the link between chronic inflammation and cancer. The Heikenwälder laboratory aims at understanding the different immune signatures of chronic inflammatory human diseases using relevant mouse models – with the final aim to generate models of chronic inflammation potentially used for pre-clinical research. Thus, the Heikenwälder laboratory focuses on comparative studies of human and animal tissues, recapitulating human disease on a histo-pathological and pathophysiological level. The laboratory engages in classical molecular biology techniques complemented with sophisticated ways to receive as much information from tissue samples through histology (e.g. light microscopy/ immune fluorescence/ FISH/ in situ hybridization), other in vivo imaging techniques (e.g. MRI) as well as through FACS analyses for tissue homogenates. At the same time, the Heikenwälder laboratory is also interested in the systemic functional effects of pathologies and the interplay between several affected non-lymphoid tissues and the immune system. Finally, testing several therapeutic compounds in a single use but also combinatorial fashion is one of the goals employing established and stratified pre-clinical mouse models.Prof. Heikenwälder publishes his work in high-ranking journals and has established himself as an international leader in the field of liver cancer. Mathias Heikenwälder is the third most frequently cited German-speaking researcher in the field of cell biology in the last 5 years and was one of the Highly Cited Researchers (Cross Fields) (Web of Science Group) in 2019, 2020 and 2021. Not only have his publications been widely cited by the research community, but they have shifted fatty liver and liver cancer research in new directions – relevant to the day-to-day management of patients with fatty liver or liver cancer. The current H-Factor of Mathias Heikenwälder is 75 (Web of Science), with 281 publications listed in Pubmed.

Born in 1975, graduated from the medical school in Aarhus, Denmark in 2003. Since then clinical training and specialization in hepatology, alongside training in clinical epidemiology. I have published more than 100 papers, most of them in the field of hepato-epidemiology. I currently do half-time clinical work, half-time research. My primary interests are alcoholic liver disease and hepatocellular carcinoma, most notably the value of surveillance for hepatocellular carcinoma among patients with alcoholic cirrhosis.

Jakob is a physician scientist with board certification in internal medicine. He was recently appointed professor of Clinical Artificial Intelligence at Technical University Dresden, Germany. His interdisciplinary research team is working at the interface of computer science and precision oncology in gastrointestinal and liver cancer. They are building and validating new AI-based biomarkers. The team is guided by a vision: physicians are trained in data science and artificial intelligence and researchers from computer science or engineering learn to identify and solve relevant clinical problems. In the last year, the team’s research studies were published in Nature Medicine and Nature Cancer, among other venues. 

Josep M. Llovet, MD, PhDis Professor of Research-ICREAin the BCLC Group, Liver Unit, IDIBAPS-Hospital Clínic of Barcelona (Spain),Founder andDirector of the Liver CancerProgram and Full Professor of Medicineat the Mount Sinai School of Medicine, New York University (USA), andDirector, Master in Translational Medicine at Faculty of Medicine, University of Barcelona. ProfessorLlovet obtained his degree in Medicine and Surgery from the University of Barcelona in 1986 and his PhD from the Autonomous University of Barcelona in 1995. Professor Llovet has been President, Secretary and Founder of the International Liver Cancer Association (ILCA) and Chairman of the European Clinical Practice Guidelines of management of liver cancer (EASL-EORTC).He has published more than 240 articles in peer-reviewed journals such as New England Journal of Medicine, Nature, Nature Genetics, Lancet, Lancet Oncology, Cancer Cell, Nature Rev Dis Primers, Nature Biotech, Nature Com, Nature Rev Clin Oncol, JCO, J Clin Invest, JNCIand Gastroenterology (total citations43.560, total impact factor2660; h index 85), more than 50chapters of books, and has delivered more than500 lectures.He isSenior Editor of Clinical Cancer Research. Of note, he has been recognized as a) Top-1% cited researcher in Thomson Reuters, 2014-2016, and b) #1 Most cited investigator in Spain, period 1997-2011. He has devoted the past 20 years of his career studying the pathogenesis and treatment of liver cancer, and has receivedthe AACR-Landon International Award (2009)for leading the International HCC Genomic Consortium, the International Hans Popper award (2012), Premi Josep Trueta (2013)and was nominated asFellow of the American Association for the Study of Liver Diseases(FAASLD-2015). He has received competitive funding for62 projects (total >€14M) including the European Commission (FP7-HEALTH, HEPTROMIC, 2010; Horizon 2020: HEP-CAR2016), DOD 2016and the US National Institute of Health(R01, 2008; P01-NCI designation 2015), the Spanish National Health Institute, I+D Program and from the Asociación Española Contra el Cancer. He is member of leadership committees in IDIBAPS-Hosp Clínic (Executive Committee) and in Mount Sinai (Executive Management Committee, Tisch Cancer Institute).

Prof. Dr. med. Tom Lüdde is Professor and Chair of the Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Germany. He studied Medicine and received a PhD at Hannover Medical School (Germany), where he also started his medical training in Gastroenterology and Hepatology. He did a research fellowship at the Lineberger Center at the University of North Carolina (USA) and a postdoc at the European Molecular Biology Laboratory (EMBL). He then continued his medical training at the University Hospital in Aachen (Germany), where he was appointed Professor. Tom Lüdde’s main research interests are inflammation in metabolic liver disease and cancer and artificial intelligence and deep learning in gastrointestinal diseases and cancer. He is the recipient of the Ernst Jung Career Advancement Award and the Thannhauser Award from the German Association of Digestive Disease (DGVS).

Vincenzo Mazzaferro MD PhD is full Professor of Surgery at the University of Milan and Director of the Gastro-Intestinal Surgery and Liver Transplantation Unit at the Istituto Nazionale Tumori (National Cancer Institute – INT) of Milan, Italy.

He graduated cum laude at the University of Turin (Italy) and was trained and board certificated in General Surgery and in Oncology at the University of Milan (Italy) and in Liver Surgery and Transplantation at the University of Pittsburgh (USA).

Along the years, both in USA and in Italy he has developed several successful clinical and experimental projects in liver oncology and transplantation and leaded research projects focused on innovative approaches to liver diseases, particularly related to cancer. He is currently in charge of the HPB (hepato-pancreatic-biliary) oncology program in the oldest and most active comprehensive cancer Institution in Italy and is fully certified for conducting registration and investigator-driven clinical trials from phase I to IV.

Through validated results and cutting-edge clinical research he has contributed to a large number of national and international collaborations. For his scientific contribution to the advancement of surgical and medical oncology he has awarded by renowned scientific and professional Societies such as the Italian Association of Cancer Research, the European Association for the Study of the Liver, the Société Française de Chirurgie Digestive, the American Association of Cancer Research, the Cardiovascular and Interventional Radiological Society of Europe and the City of Milan. He is a member of the major Liver, Surgery and Transplant Societies and has served as Associated Editor for the Journal of Hepatology. In addition he is in the board of major Journals devoted to surgery, hepatology, oncology and transplantation.

Professor Mazzaferro is the inventor of the Milan Criteria for liver transplantation in cancer patient, adopted all over the world. He shares patented devices in surgical oncology. He is the Coordinator of the ENET Center of Excellence of the INT-Milan. In the last 4 years he has co-authored the EASL clinical practice guidelines for hepatocellular carcinoma, the updated multi-expert BCLC algorithm and the Lancet Commission report on the Liver.

Professor Mazzaferro leads a high-volume clinical Unit accounting for about 900 admissions per year in patients treated for HPB and upper gastrointestinal cancer. He has an outstanding operatory record in all kind of procedures regarding HPB and upper G.I. surgery. He has authored 420 publications in international peer-reviewed medical Journals and has delivered more than 500 lectures. He is an appreciated teacher and mentor of many students and young physicians belonging to the University of Milan and to international pre- and post-graduate programs.

Tim Meyer is Professor of Experimental Cancer Medicine at UCL and Honorary Consultant in Medical Oncology at the Royal Free and ULCH Hospitals. He is Director of the Royal Fee London Clinical Research Facility and the UCL Experimental Cancer Medicine Centre. He specialises in the management of hepatocellular and leads a large portfolio of clinical trials. He is Treasurer for ILCA, Secretary of HCC UK, a member of the NCRI Hepatobiliary subgroup and European representative on the NCI Hepatobiliary Taskforce.

Prof. Cindy Neuzillet is M.D., Ph.D., H.D.R., head of GI Oncology at Curie Institute, Saint Cloud, France. She was board certified in Hepato-Gastro-Enterology in 2013 and in Oncology in 2014. After an Oncology fellowship in Paris, she spent 18 months at Barts Cancer Institute (Prof. Kocher’s lab) in London, and then 15 months at Center for Cancer Research of Toulouse (Dr. Bousquet’s lab), for her Ph.D., aiming at establishing a classification of cancer-associated fibroblasts in pancreatic cancer (J Pathol 2019, awarded by the Jass Prize for Research Excellence 2019; and J Pathol 2022). Her research work is focused on interactions between tumor cells, stromal cells, and intra-tumoral microbiota in pancreatic and biliary tract cancers. She is a lead member of the PRODIGE “Pancreatic and Biliary Tract Cancers” working group for clinical trials and national PI of several multicenter trials in this field (including GERCOR IMMUNOBIL PRODIGE 57, NCT03704480). She co-led the working group of national guidelines for pancreatic cancer management in France (TNCD, Dig Liver Dis 2018) and the working group for cholangiocarcinoma management (AFEF 2022). She is President of the French Pancreatic Club (CFP) and President of the French Association for Biliary Tract Cancer and Diseases (ACABi), and chair of the Pancreatic Cancer EORTC task force.

Valérie Paradis, MD PhD and Professor in Pathology, is the chairman of Pathology department (Beaujon hopsital) and leader of the INSERM team “From inflammation to neoplasia in digestive diseases” (INSERM UMR 1149 Paris). Fields of interest and research include pathological and molecular aspects of liver fibrosis, vascular diseases, and tumorigenesis with a specific interest in tumor heterogeneity. To address this later issue, her team has developed original in situ proteomic approach (MALDI imaging) for identification of tissue signatures and biomarkers, and ex vivo culture model using thin tumor slices and organoids for evaluation of drug therapy. V. Paradis is chairing the specialty “Epithelium: interface structure” (Master 2 “Cellular Biology-Physiology-Pathology”). She is co-coordinator of the DHU UNITY “Unmet Needs for Innovation in HepaTology and GastroenterlogY” and task leader of the RHU QUID-NASH aiming to identify non-invasive diagnostic markers of NASH in diabetic patients. She is coordinating a collaborative FHU project MOSAIC aiming to identify imaging signatures through integration of radiological and histological features and Artificial intelligence. She is a member of International groups of liver pathologists (Laennec & Elves), Scientific commissions Research Institutes (INSERM, ANRS), Associate Editor (J Hepatol and WHO Classification of Digestive tumors 2019).

Dr David James Pinato is an NIHR Academic Clinical Lecturer in Medical Oncology working within the Division of Surgery and Cancer at Imperial College, London. He has worked across a number of institutions in Europe and UK and has undertaken his postgraduate training in Medical Oncology at the Royal Marsden Hospital and at Imperial College in London. David devoted his research efforts to study the role of inflammation as a molecular mechanism underlying the pathogenesis and progression of Hepatocellular Carcinoma, with a particular focus on intermediate-stage HCC. His studies, supported by international collaborations, eventually led to the qualification of novel prognostic and predictive biomarkers. He is affiliated to the Imperial College Liver Cancer study group, having led a number of translational studies in intermediate-advanced HCC.

Helen Reeves graduated from Nottingham Medical school in 1990, moving shortly afterwards to Newcastle-upon-Tyne under the mentorship of Professor Oliver James. She completed a PhD studying cell signaling pathways in liver fibrosis and then worked as a post-doctoral scientist with Professor Scott Friedman at Mount Sinai Medical School in New York, funded by an AASLD Fellowship, studying aspects of the molecular pathogenesis of cancers. Presently she is Professor of Liver Cancer at Newcastle University and is the clinical lead for the care of patients with hepatocellular carcinoma in Northern England. She has been a scientific committee member for the British Association for Cancer Research, and served as the UK representative on the governing board for the European Association for Study of the Liver from 2013 until 2016. She currently serves on the EASL Education Committee. She is a founding member for HCC-UK and remains an active committee member. Her particular research focus is on non-alcoholic fatty liver disease related HCC and the identification of improved stratification biomarkers and targeted therapies. She has a programme grant from Cancer Research UK and leads the CRUK, AECC, AIRC jointly funded HUNTER: Hepatocellular Carcinoma Expediter Network.

My career in Medicine started in 2001 when I graduated from Medical School. I did my training in Internal Medicine in Castro Rendon Hospital (Neuquén, Patagonia) and then, moved to the Hospital Italiano in Buenos Aires where I did my Hepatology and Liver Transplantation training (2005-2007). In 2008 I moved to Barcelona to enter the BCLC, Liver Unit in Hospital Clínic of Barcelona as a pre-doctoral fellow and I have a faculty position in the Liver Unit since 2016. Upon completion of a Master in Liver Research and a Degree in Statistics, I developed my Doctoral Thesis under the guidance of Professor Bruix. My area of interest has been the development of prognostic models for patients with liver cancer and evaluation of treatment options with special emphasis in systemic therapy. Additionally, I obtained a Degree in Immuno-Oncology at the University of Navarra that has facilitated the opening of a new area of research about immune modulation and cancer emergence after antiviral treatment.During my career focused in clinical research in liver cancer I have authored 58 manuscripts ORCID ID 0000-0002-5711-9534 with a total Impact Factor of 527.071 and an H-index=26. My current research at the Oncology Unit of Hopsital Clinic is funded by competitive grants where I am the Principal Investigator and by grants and contracts where I am a main collaborator both at the national and international level. At the same time, I am responsible for the coordination of the educational events and short-term fellowship visits at the BCLC, while also being the mentor of three predoctoral trainees.I regularly review manuscripts for the major Hepatology journals and have been member of the Governing Board of the Spanish Association for the Study of the Liver and ILCA.

Lorenza Rimassa graduated at the Medical School of the University of Milan (Italy) in 1993. Her post-graduate education continued with a Medical Oncology degree, achieved in 1997. She worked at the San Raffaele Institute and at the National Cancer Institute in Milan, as clinical and research fellow. Since 1998 she is working at Humanitas Cancer Center, IRCCS Humanitas Research Hospital, in Milan. She is Deputy Director of the Medical Oncology Unit and Head of the Gastrointestinal (GI) Oncology Section. Since October 2019 she is Associate Professor of Medical Oncology at Humanitas University, since April 2020 Member of Academic Board of the PhD Program in Datascience in Medicine & Nutrition (DASMEN), and since November 2020 Director of the Residency Program in Medical Oncology at the same University, in Milan. She has a long-standing interest in the field of clinical and translational cancer research, and she has been involved in more than 100 clinical trials. From 2005, she focused her interest on patients with GI cancers, treated with new drugs in national and international clinical trials. From 2012, she is principal investigator, member of the steering committee, or of the data monitoring committee for national and international, multicenter, phase 1-2-3 clinical and translational trials of new drugs -chemotherapy, small molecules, monoclonal antibodies, immuno-oncology drugs- for GI cancers, in particular hepatocellular carcinoma and biliary tract cancers. She is Treasurer of the International Liver Cancer Association (ILCA) and member of the ILCA Executive Committee and Governing Board, she holds the position of Special Expert – International Trials Europe on the Hepatobiliary Task Force (HB TF) of the National Cancer Institute (NCI, Bethesda, MD, US) Gastrointestinal Steering Committee (GISC), she is a member of EORTC Gastrointestinal Tract Cancer Group (GITCG) – Hepatobiliary (HB) Task Force, of the COST Action CA18122 (Working Group), and of the Scientific Committee of the Suisse Liver Cancer Foundation. She is also a member of the Italian Multi-Society Guidelines Writing Committee on Hepatocellular Carcinoma. She is a member of the European Society for Medical Oncology (ESMO), of the American Society of Clinical Oncology (ASCO), of the European Association for the Study of the Liver (EASL), of ILCA, and of the Italian Association of Medical Oncology (AIOM). She is author of approximately 200 articles published in peer-reviewed journals on the development of new treatments and biomarkers for GI cancers. She is Associate Editor for Liver Cancer International, and member of the Editorial Board of several journals including Journal of Hepatology, Therapeutic Advances in Medical Oncology, Cancers, Journal of Hepatocellular Carcinoma, Liver International, and Scientific Reports. She is ad-hoc reviewer for several international scientific journals. She is speaker, chair, discussant, member of the organizing and scientific committee at national and international congresses and conferences.

Maxime Ronot, MD, PhD, is Professor at the Université Paris Cité, and works in the Department of Medical Imaging at the Beaujon University Hospital in Clichy, France. His main interests are in abdominal imaging—mainly liver and pancreas diseases and tumors—, interventional abdominal oncology, and abdominal vascular diseases. Prof. Ronot is a member of several French and European societies of radiology, including the French and European Societies of Radiology, and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), and is a member of the LI-RADS steering committee. He is a member of the LI-RADS AI group, and of the CIRSE AI task force. He has authored or coauthored more than 280 articles and books. He serves as president of the French national ethics committee for medical imaging research.

Prof Dr Tania Roskams is Head of the Department of Imaging and Pathology of the University of Leuven, Leuven, Belgium. She also heads the research group Translational Cell-and Tissue Research within the same university. She is professor in Anatomy and Histology and Liver Pathology in the Medical Faculty of the University of Leuven. Prof Dr Roskams was an independent member of the Scientific Board of the United European Gastroenterology Federation (2005-2011) and a member of the Governing Board of the European Association for the Study of the Liver (2009-2012) Her research interests are the role of liver stem/progenitor cells in liver regeneration and carcinogenesis. She is also specialized in the characterization of animal models for the representativity for human diseases.

Prof. Bruno Sangro is Director of the Liver Unit and Coordinator of the HPB Oncology Area at Clínica Universidad de Navarra in Pamplona, Spain. He is also Professor of Internal Medicine and leads an active research group in the Spanish Network for Biomedical Research on Hepatic and Digestive Diseases (CIBEREHD), focused on therapeutic innovation in the field of liver cancer.

Amit Singal, MD, MS, is a Professor of Medicine and Chief of Hepatology at UT Southwestern Medical Center in Dallas, TX. He is an expert in hepatocellular carcinoma (HCC) management and serves as the Medical Director of the UT Southwestern Liver Tumor Program. Dr Singal received his medical degree from the University of Michigan Medical School, Internal Medicine residency at the University of Washington, and then completed fellowships in gastroenterology and transplant hepatology at the University of Michigan Medical Center. Dr Singal is board certified in gastroenterology and transplant hepatology. 

Dr Singal’s research focuses on prevention, screening and treatment of HCC, including evaluation of interventions to improve early tumor detection and reduce HCC-related mortality. He has published more than 250 peer-reviewed articles and received grants from the National Institutes of Health (NIH), Cancer Prevention Research Institute of Texas (CPRIT), and the Department of Defense. For his work, he has been awarded the David Bruton Professorship in Clinical Cancer Research, Dedman Family Scholar in Clinical Care, and Blue Faery Award for Excellence in Liver Cancer Research. 

Arndt Vogel, MD, is managing senior consultant and professor in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.  He is head of the GI-Cancer Center and of the center for personalized medicine at Medical School Hannover.  

Prof. Vogel’s scientific focus is the translational and clinical research in gastrointestinal cancer. Since 2004, he is leading a basic research group interested in the pathogenesis of GI-cancers with a special focus on hepatobiliary cancers and precision medicine. Arndt Vogel is a clinical investigator in oncology since 2006 and has served as principal investigator on numerous clinical trials. He is author or co-author of more than 260 articles published in peer-reviewed journals including Lancet, Lancet Oncology, Cancer Cell, Gastroenterology, and Hepatology.

Prof. Vogel is member of societies including ESMO, ASCO, and EASL. He is member and chairman of Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. Within ESMO, he is member of the ESMO Guidelines Steering Committee. Dr. Vogel has responsibilities in the establishment of the national guideline and is the coordinator of the ESMO clinical practice guideline on the management of hepatocellular carcinoma and biliary tract cancer.  

Jessica Zucman-Rossi is Professor of Medicine at University Paris Descartes, within the department of Oncology at the European Hospital Georges Pompidou (AP-HP). She is the director of the Cordeliers Center of Research and of the team “Functional Genomics of Solid Tumors”, with a focus on liver, mesothelial and renal tumors. Her team aims to develop basic genomic approaches based on human tumors analyses to identify new mechanisms of tumorigenesis and to transfer this knowledge into biomarkers that could be introduced in clinical care. In particular, the group was pioneer in the elucidation of the molecular classification of benign and malignant liver tumors. Currently, she is vice-Chair of the AASLD SIG Hepatobiliary neoplasma, she acts as Editor in Chief for JHEP Reports.